Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.44 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341451 | 0.91 | KDM4E (0.49) | KDM4EALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL4329328 | 0.88 | RECQL (0.60) | KDM4EALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL4332486 | 0.87 | KDM4E (0.48) | KDM4EALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL2862186 | 0.84 | SMN1; SMN2 (0.56) | MAPK1SMN1; SMN2DYRK1A | |
| SCHEMBL4333984 | 0.84 | PTAFR (0.51) | KDM4EALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL13927664 | 0.84 | KDR (0.49) | KDM4EALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL2867437 | 0.83 | CSNK1D (0.47) | MAPK1KMT2APTAFRMAP2K4MAP2K7 | |
| SCHEMBL4338790 | 0.81 | RECQL (0.48) | KDM4EALDH1A1LMNAKMT2AHTT | |
| SCHEMBL4328143 | 0.81 | HPGD (0.53) | KDM4EALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL4341432 | 0.80 | ALDH1A1 (0.47) | KDM4EALDH1A1LMNAMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | KDM4E 2531/4885ALDH1A1 1588/4885LMNA 1893/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | KDM4E 2531/4885ALDH1A1 1588/4885LMNA 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.